We identify new chemical classes from nature and turn them into high-value products with real-world impact
We are currently discovering and developing the next generation of antimicrobials
Septoria (wheat)
Septoria
(wheat)
20% of the global nutrient intake comes from wheat
Septoria destroys up to 50% of a farmer’s yield
20% of the global nutrient intake comes from wheat
Septoria destroys up to 50% of a farmer’s yield
Aspergillosis
Aspergillosis
1.8M deaths per year
30%-50% mortality rates when treated
1.8M deaths
per year
30% - 50% mortality
rates when treated
Gram negatives
Gram
negatives
3 million deaths per year
Biggest threat to modern hospitals
3 million deaths per year
Biggest threat
to modern hospitals
1 compound
2 compounds
4 compounds
Novel
class
In vitro
testing
In planta
testing
Scale-up &
formulation
Small
fields trials
Novel class
In vitro testing
In planta testing
Scale-up & formulation
Small fields trials
Market size
$3.1 Bn
RESULTS
Our 3 leading programmes will have global impact
SEPTORIA
Protecting Wheat from Septoria
Wheat constitutes 20% of the global calorie intake but is under threat from Septoria
Farmers lose up to 50% of their yield, with current fungicides under increasing threat from resistance
Bactobio has discovered multiple new fungicidal classes that are effective, safe, and bypass resistance
We are currently testing the most developed new classes on the field and expect to create market-leading products that help protect the world’s food supply
ASPERGILLOSIS
Next-Generation antifungals: Combating Aspergillosis
Invasive Aspergillosis is a rapidly progressing, highly lethal fungal infection that threatens the lives of immunocompromised patients worldwide
No new antifungal class has been brought to market in 20 years and rising resistance means that patients now often die even when treated
We are advancing a vital new line of defense. We have identified several novel antimicrobial classes with >99% in vitro efficacy and low early toxicity
Our new classes have the potential to protect millions of patients’ lives worldwide
GRAM NEGATIVES
​New classes and synergies to treat Gram Negatives Infections
Drug-resistant Gram-negative bacteria especially target immune-compromised patients in hospitals – putting severe strains on our healthcare system
Gram Negatives are often deadly and our clinical arsenal is failing with no therapeutic breakthroughs in the last 30 years
We have discovered a new antibiotic class that is highly effective, looks safe, and works in synergy with the antibiotic of last resort, colistin
​
Our new class has the potential to save the lives of millions, while also protecting our healthcare system
If you want to work with us please